There are currently 2700 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
SIRT With Tremelimumab and Durvalumab for Resectable HCC
NCT05701488
Recruiting
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Register for Updates
Cortical-Basal Ganglia Speech Networks
NCT04286308
Recruiting
In this research study the researchers want to learn more about brain activity related to speech perception and production.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/26/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Parkinson Disease, Essential Tremor, Dystonia
Register for Updates
Computational Neuroscience of Language Processing in the Human Brain
NCT05222594
Recruiting
Language is a signature human cognitive skill, but the precise computations that support language understanding remain unknown. This study aims to combine high-quality human neural data obtained through intracranial recordings with advances in computational modeling of human cognition to shed light on the construction and understanding of speech.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/26/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Language, Epilepsy
Register for Updates
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia
NCT05661084
Recruiting
This project aims to examine the efficacy of remote, caregiver-led tES/brain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/26/2024
Locations: Hinda and Arthur Marcus Institute for Aging Research, Boston, Massachusetts
Conditions: Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation
Register for Updates
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
NCT03741777
Recruiting
According to the American Society of Anesthesiologists (ASA) fasting guideline for patients undergoing elective surgery, the 2-hour fasting period is suggested for clear oral fluid (including water, pulp-free juice and tea or coffee without milk). This guideline does not give any suggestions for proper volume of clear oral fluid intake. This study is a prospective randomized control trials in children aged 13 through 17 years who are scheduled for an elective upper GI endoscopy procedure in the... Read More
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
06/24/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Fasting, Gastric Emptying
Register for Updates
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
NCT05028829
Recruiting
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Liver Fibroses, Cirrhosis
Register for Updates
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
NCT05795595
Recruiting
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Research Site 6, Boston, Massachusetts
Conditions: Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Register for Updates
Permissive Hypotension After Cardiac Surgery
NCT06476613
Recruiting
The objective of this pilot randomized controlled trial is to demonstrate the feasibility of implementing a pragmatic clinical trial randomizing patients to permissive hypotension versus usual care and to determine the impact of permissive hypotension on vasopressor exposure, ICU length of stay, markers of end organ perfusion, and clinically relevant patient outcomes. The data collected from this pilot study will be used as preliminary data for study design and grant applications for a larger mu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Surgery
Register for Updates
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
NCT05077800
Recruiting
The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: * 9-ING-41 * Losartan * Ferumoxytol * FOLFIRINOX (made up of 4 different drugs): * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
Register for Updates
VIGOR: Virtual Genome Center for Infant Health
NCT05205356
Recruiting
This study will provide rigorous evaluation of implementing a virtual genome center into community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minority (URM) populations and will enhance capacity for providers and health systems to utilize highly sp... Read More
Gender:
ALL
Ages:
Between 0 days and 99 years
Trial Updated:
06/21/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Genetics Disease, Genetics/Birth Defects, Genetic Predisposition to Disease
Register for Updates
Application of a Systematic Developmental Assessment to a Novel Population: Infants With Rare Genetic Disorders
NCT03967743
Recruiting
The main objective of this study is to apply a well-established model of developmental surveillance (which evolved to characterize the outcomes of very low birth weight infants) to infants with genetic disorders. A novel clinical model for infants with rare genetic disorders has been created as a joint initiative between the Division of Newborn Medicine's NICU Growth and Developmental Support Programs (NICU GraDS) program and the Division of Genetics at Boston Children's Hospital (BCH). This stu... Read More
Gender:
ALL
Ages:
4 years and below
Trial Updated:
06/19/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Genetic Disease, Genetic Syndrome, Genetic Predisposition to Disease, Development, Infant, Development, Child
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Dana Farber Cancer Institute-Hematology/Oncology, Boston, Massachusetts
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates